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A B S T R A C T
PET using the amino-acid O-(2-18F-ﬂuoroethyl)-L-tyrosine (18F-FET) is gaining increasing interest for brain tu-
mour management. Semi-quantitative analysis of tracer uptake in brain tumours is based on the standardized
uptake value (SUV) and the tumour-to-brain ratio (TBR). The aim of this study was to explore physiological
factors that might inﬂuence the relationship of SUV of 18F-FET uptake in various brain areas, and thus aﬀect
quantiﬁcation of 18F-FET uptake in brain tumours. Negative 18F-FET PET scans of 107 subjects, showing an
inconspicuous brain distribution of 18F-FET, were evaluated retrospectively. Whole-brain quantitative analysis
with Statistical Parametric Mapping (SPM) using parametric SUV PET images, and volumes of interest (VOIs)
analysis with fronto-parietal, temporal, occipital, and cerebellar SUV background areas were performed to study
the eﬀect of age, gender, height, weight, injected activity, body mass index (BMI), and body surface area (BSA).
After multivariate analysis, female gender and high BMI were found to be two independent factors associated
with increased SUV of 18F-FET uptake in the brain. In women, SUVmean of 18F-FET uptake in the brain was 23%
higher than in men (p < 0.01). SUVmean of 18F-FET uptake in the brain was positively correlated with BMI
(r = 0.29; p < 0.01). The inﬂuence of these factors on SUV of 18F-FET was similar in all brain areas. In con-
clusion, SUV of 18F-FET in the normal brain is inﬂuenced by gender and weakly by BMI, but changes are similar
in all brain areas.
1. Introduction
The 18F labelled amino acid O-(2-[18F]-ﬂuoroethyl)-L-tyrosine (18F-
FET) can be produced with high eﬃciency. Its favourable properties
such as high in vivo stability, high tumour to background contrast, and
tissue speciﬁc tracer kinetics make it an ideal tracer for brain tumour
assessment (Langen et al., 2017). Accordingly, positron emission to-
mography (PET) using 18F-FET is gaining increasing clinical interest,
and has been recently recommended by the Response Assessment in
Neuro-Oncology (RANO) working group as an additional tool in the
diagnosis of brain tumours (Albert et al., 2016). In detail, many studies
investigated the potential of this radiotracer in diﬀerential diagnosis
and grading of brain tumours (Jansen et al., 2012; Pöpperl et al., 2007;
Rapp et al., 2013), delineation of tumour extent (Pauleit et al., 2005;
Stockhammer et al., 2008; Mehrkens et al., 2008; Misch et al., 2015),
treatment monitoring (Galldiks et al., 2012, 2013), and prognostication
(Jansen et al., 2015).
A few studies have tried to evaluate 18F-FET uptake by
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pharmacokinetic modelling but without clinical gain. Any advantage
over simpler approaches to characterize 18F-FET uptake has not been
reported (Langen et al., 2017). Today, semi-quantitative analysis using
the standardized uptake value (SUV) is the standard approach to de-
termine 18F-FET uptake in brain tumours. SUV is calculated by dividing
the radioactivity (kBq/ml) in the tissue by the radioactivity injected per
gram of body weight (Langen et al., 2017). Generally, 18F-FET uptake in
brain tumours is expressed as maximum and mean SUV (SUVmax and
SUVmean) and a number of studies have used SUV as a direct measure to
quantify 18F-FET uptake in the tumour (Calcagni et al., 2011; Pöpperl
et al., 2004, 2006, 2007). Moreover, this parameter has been applied to
delineate the target volume for radiotherapy planning using an SUV of
3–5 or a fraction of SUVmax (Rickhey et al., 2008; Vees et al., 2009; D. C.
Weber et al., 2008). In the majority of studies, however, tracer uptake
in the tumour was quantiﬁed by the ratio of SUVmax or SUVmean in the
tumour to the SUVmean in a background region in the contralateral
hemisphere expressed as maximal and mean tumour-to-brain ratios
(TBRmax and TBRmean) (Jansen et al., 2012, 2015; Mehrkens et al.,
2008; Misch et al., 2015; Pauleit et al., 2005; Pöpperl et al., 2007; Rapp
et al., 2013; Stockhammer et al., 2008). This method is based on the
assumption that 18F-FET uptake in the normal brain is relatively
homogeneous although there is some discussion about the optimal
positioning of the region of interest in the normal brain (Unterrainer
et al., 2017). Nevertheless, it cannot be excluded that physiological
variations of SUVmean of 18F-FET uptake in background could inﬂuence
TBRs and the results of semi-quantitative analysis.
It is well-known that age and gender inﬂuence cerebral metabolism
as measured for example by PET using the glucose analogue 18F-
ﬂuorodeoxyglucose (18F-FDG) (Hsieh et al., 2012; Kakimoto et al.,
2016; Van Der Gucht et al., 2015; Yoshizawa et al., 2014). Although
amino acid transport in the brain as reﬂected by 18F-FET uptake is not
directly associated with metabolic processes (Langen et al., 2017), a
recent study suggest that epileptic neural activity may lead to tem-
porarily increased 18F-FET uptake (Hutterer et al., 2017). Furthermore,
it has been reported that pharmacotherapy with dexamethasone in-
creases 18F-FET uptake in the normal brain tissue leading to a reduction
of the TBR (Stegmayr et al., 2016).
The aim of this study was to assess the eﬀect of various physiolo-
gical factors upon 18F-FET uptake in the normal brain tissue. For this
purpose, 18F-FET uptake in the brain was evaluated in a large cohort of
subjects with an inconspicuous distribution of 18F-FET and which were
rated as “negative scans” with respect to brain tumour diagnosis.
Indeed, brains with strong abnormalities in radiotracer uptake are not
compatible with whole-brain SPM analysis. SUVmean of 18F-FET in the
brains of this cohort was correlated with diﬀerent parameters such as
age, gender, weight, height, injected dose, body mass index (BMI), and
body surface area (BSA).
2. Materials and methods
2.1. Subjects
Out of a series of patients with suspicious brain lesions who were
admitted for 18F-FET PET to the Institute of Neuroscience and Medicine
in Jülich (Germany) from February 2010 to April 2017, 107 scans
which revealed no abnormality in 18F-FET PET and which had been
rated in the medical reports as “negative scans” with respect to tumour
diagnosis, were retrospectively identiﬁed by two experienced nuclear
physicians (AV and GS). Negative scans were deﬁned as showing 18F-
FET uptake in the suspected lesion area (identiﬁed by corresponding
MR images) to be indistinguishable from that of the normal brain
within a TBRmax range of 0.9–1.1, which is in line with the expectable
background SUV changes (± 8%) in the brain for this radio-
pharmaceutical (Unterrainer et al., 2017). Other inclusion criteria for
further data evaluation were age > 18 years, no pre-treatment with
radio- or chemotherapy or received therapy with dexamethasone, and
complete coverage of the brain by the PET acquisition which was es-
sential for data analysis. In the majority of patients (91), no histological
examination was performed and there was no evidence for an ag-
gressive tumour. In 16 patients, however, a biopsy was performed
owing to the conspicuous MRI despite negative FET PET. Histo-
pathology yielded an astrocytoma WHO grade II in four cases, astro-
cytoma WHO grade III in six cases, oligoastrocytoma WHO grade II in
two cases, oligoastrocytoma WHO grade III in one case and oligoden-
droglioma WHO grade II in one case. In two cases, histology revealed
no evidence of tumour. For each subject, data of age, gender, weight
and height were collected. Subsequently, BMI [kg/m2] was calculated
by dividing the weight [kg] by the square of the height [m2] (Gorber
et al., 2007). BSA [m2] was calculated using weight and height and the
Gehan and George formula (Gehan and George, 1970).
Subjects included in the present study were from 18 to 84 years old
(45.4 ± 16.5 years old, 40 women, 41 hybrid PET/MR scans). Detailed
characteristics of subjects are available in Table 1. No diﬀerence in age,
type of PET scanner, injected dose, or BMI was noticed between women
and men. However, weight, height, and BSA were higher in men than in
women (p = 0.01). All subjects gave written informed consent for the
investigations and the local ethics committee approved the evaluation
of retrospectively collected data. Moreover, all subjects from our in-
stitution are informed that their medical data can be rendered anon-
ymously and used for scientiﬁc purposes prior to providing consent.
2.2. 18F-FET PET acquisition
The amino acid 18F-FET was produced and applied as described
previously (Galldiks et al., 2012). According to the German guidelines
for brain tumour imaging using labelled amino acid analogues, all
subjects fasted for at least 12 h before PET scanning (Langen et al.,
2011). Dynamic PET studies were acquired up to 50 min after in-
travenous injection of 2.8 ± 0.3 MBq of 18F-FET/kg of body weight.
PET imaging was performed either on an ECAT Exact HR+ PET
scanner in 3-dimensional mode (Siemens Medical Systems) (axial ﬁeld
of view, 15.5 cm; image resolution, 6 mm) or simultaneously with MR
imaging using a BrainPET insert. The BrainPET is a compact cylinder
that ﬁts in the bore of the Magnetom Trio MR scanner (axial ﬁeld of
view, 19.2 cm; optimum image resolution, 3 mm) (Herzog et al., 2011).
Iterative reconstruction parameters were 16 subsets, 6 iterations using
the OSEM algorithm for ECAT Exact HR+ PET scanner and 2 subsets,
32 iterations using the OP-OSEM algorithm provided by the manu-
facturer for the BrainPET, with correction for random, scattered coin-
cidences, and dead time for both systems. Attenuation correction for the
ECAT Exact HR+ PET scan was based on a transmission scan, and for
the BrainPET scan on a template-based approach. This attenuation map
template was obtained from 8 diﬀerent subjects recorded with the
ECAT Exact HR+ PET (Siemens Medical Systems) and which is spa-
tially co-registered to the MPRAGE scan of the individual patient using
SPM (Filss et al., 2014; Herzog et al., 2011; Kops et al., 2014). Sixty-six
Table 1
Characteristics of subjects.
Women
n = 40
Men
n = 67
p-Value⁎
Age 44.1 ± 13.9 46.2 ± 17.9 0.51
Hybrid PET/MR scans 19 (48%) 22 (33%) 0.13
Injected dose [MBq/kg] 2.8 ± 0.3 2.7 ± 0.3 0.10
Weight [kg] 78.9 ± 17.8 87.2 ± 12.7 0.01⁎
Height [cm] 167.5 ± 6.9 179.4 ± 7.2 0.01⁎
BMI [kg/m2] 28.2 ± 6.4 27.1 ± 3.6 0.33
BSA [m2] 1.9 ± 0.2 2.1 ± 0.2 0.01⁎
BMI: body mass index.
BSA: body surface area.
⁎ p-Value for comparison between women and men.
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subjects (48.2 ± 16.6 years, 21 women, 32%) had their examination
on the ECAT PET, 41 (40.9 ± 15.4 years, 19 women, 46%) in the PET/
MR system (p = 0.03 for the comparison of age between two groups,
non-signiﬁcant for the comparison of gender). For the evaluation of 18F-
FET uptake, summed PET images over the period of 20–40 min post-
injection were used.
2.3. SPM analysis
Whole-brain statistical analysis was performed at voxel-level using
SPM8 software (Wellcome Department of Imaging Neuroscience,
University College, London, UK). PET images were spatially normalized
to an in-house adaptive template derived from MR and 18F-FET PET
images of 14 scans performed in the hybrid PET/MR system (Gispert
et al., 2003). Brieﬂy, the in-house PET template was built on the basis of
previous MRI-aided spatial normalization of 14 subjects
(39.8 ± 15.6 years old, 12 women). PET scans of each subject were
initially co-registered to its corresponding MRI using the co-registration
algorithm included in the SPM8 package. After this step, the MR images
of the subjects were normalized to the Montreal National Institute
(MNI) MRI template, also using the algorithm provided with SPM8, and
the resulting deformation ﬁeld was applied to the PET scans. The ﬁnal
template was built by averaging these normalized PET images and
applying a 3-dimensional Gaussian ﬁlter (FWHM 8 mm3). The dimen-
sions of the resulting voxels were 2 mm3. This original adaptive 18F-FET
PET template is available in Fig. 1A and in Supplementary materials.
Then, initial PET images were normalized to this in-house adaptive
template, using the algorithm provided by SPM8 and thereafter, nor-
malized PET images were smoothed with a 3-dimensional Gaussian
ﬁlter (FWHM 8 mm3).
In order to obtain parametric SUV PET images, normalized PET
images were divided by the value of the injected dose for each subject
[MBq/g] according to the deﬁnition of SUV value:
SUV r
a w
=
′
" ( / )
"
where r is the radioactivity concentration [MBq/ml] within a volume of
interest (VOI), in the present study the overall brain area, a′ is the
decay-corrected amount of injected 18F-FET [MBq], the decay-correc-
tion being constant in this current study because all subjects performed
their scans at the same time after injection, and w is the weight of the
subject [g], which is used as surrogate for a distribution volume of the
tracer. SUVs used in this study are dimensionless under the assumption
that 1 ml of tissue is equivalent to 1 g of body weight (W. A. Weber
et al., 2008). Finally, a correction for the voxel size was applied by
dividing each image by 8 (voxel size of resulting images is 8 mm3) in
order to obtain a radioactivity concentration in 1 ml.
Statistical analysis was performed with a linear model of regression
analysis for age, BMI, and BSA eﬀects, with gender, and type of PET as
nuisance covariates. Analysis of variance (ANOVA)-test comparisons
were performed for: i) gender with age, BMI, BSA, and type of PET as
covariates, and ii) type of PET with age, gender, BMI, and BSA as
covariates. SPM (T) maps were obtained at a threshold (voxel-level
signiﬁcance) of p < 0.001 uncorrected, but corrected for cluster vo-
lume as recommended to avoid type II errors (Lieberman and
Cunningham, 2009). The anatomical localization of the most signiﬁcant
voxels was then identiﬁed using MNI coordinates.
In order to extract the quantitative values of SUVmean of 18F-FET,
several Volumes of Interest (VOIs) were applied at individual level
using Marsbar® (Marseille, France), including a large crescent shape
fronto-parietal area placed on the semi-oval centre as recommended
(Unterrainer et al., 2017), but also in the temporal, occipital, and cer-
ebellar areas. Afterwards, it was evaluated whether the SUVmean of 18F-
FET in these brain areas is diﬀerently inﬂuenced by various factors.
These VOIs are illustrated in Fig. 1B, C, D, and E.
2.4. Statistical analysis
Quantitative variables are expressed as mean ± standard devia-
tion, and categorical variables as percentage. t-Tests were performed for
the comparison of means between two quantitative variables with
normal distribution and Chi-square tests for comparison between two
categorical variables. Pearson coeﬃcients were used for correlation
analysis. A linear regression model was applied for multivariate
Fig. 1. Slice sections of A, original 18F-FET PET template calculated from images of 18F-FET PET negative scans of 14 patients (39.8 ± 15.6 years old, 12 women) and volumes of interest
deﬁned for the background uptake of 18F-FET in the fronto-parietal (B), the temporal (C), the occipital (D), and the cerebellar (E) areas.
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analysis. A p < 0.05 was determined as signiﬁcant. Statistical analysis
based upon SPM is mentioned above.
3. Results
3.1. SPM analysis
SUV of 18F-FET was higher in women than in men in diﬀuse cortical
areas involving frontal, parietal, temporal, occipital lobes, and cere-
bellum (p < 0.001 uncorrected, k > 356) (Fig. 2).
Moreover, BMI was positively correlated with higher SUV of 18F-
FET in diﬀuse cortical areas involving frontal, parietal, temporal, oc-
cipital lobes and cerebellum (p < 0.001 uncorrected, k > 332)
(Fig. 3). However, the extent of ﬁndings was lower than for gender
eﬀects (277 vs. 818 cm3).
No statistical signiﬁcant ﬁnding was observed for the eﬀects of age,
BSA and type of PET.
3.2. Marsbar analysis and inﬂuence on SUVmean VOI
An univariate analysis was calculated for eﬀects of age, gender, type
of PET, weight, height, injected activity, BMI, and BSA on SUVmean VOI.
Gender, height, and BMI signiﬁcantly inﬂuenced SUVmean of 18F-FET in
the fronto-parietal VOI. In detail, SUVmean of 18F-FET in women was
23% higher than in men (p < 0.01) as shown in box-plots in Fig. 4.
Moreover, SUVmean of 18F-FET was weakly positively correlated with
BMI, in overall population and for women (r = 0.29, 0.33 p < 0.04)
but not in men (p = 0.14) as illustrated in Fig. 5, and negatively cor-
related with height, in overall population and in women (r =−0.40
and −0.32 respectively; p < 0.05) but not in men (p = 0.95). In
addition, SUVmean of 18F-FET was 12% higher in obese subjects
(n = 25, deﬁned as BMI ≥30 kg/m2, (Gorber et al., 2007)) than in
subjects with normal weight (1.42 ± 0.31 vs. 1.27 ± 0.26,
p = 0.02).
In multivariate analysis using a linear regression model with all
factors mentioned above and taking into account inter-correlated
parameters, only gender and BMI remained as signiﬁcant parameters
inﬂuencing SUVmean of 18F-FET in the brain tissue VOI
(SUVmean = 0.257 × female gender + 0.014 × BMI + 1.080; p <
0.01).
For the evaluation of regional 18F-FET distribution, the previously
deﬁned VOIs (temporal, occipital, and cerebellar) were inﬂuenced by
gender, height, and BMI in the same way as the fronto-parietal VOI
(increase of 24% of SUVmean of 18F-FET in women in comparison to
men, and a correlation coeﬃcient with height and BMI of −0.40 and
0.31 for the temporal VOI, 22%,−0.41 and 0.37 for the occipital VOI,
and 26%,−0.39 and 0.33 for the cerebellar VOI, p < 0.01). Thus, the
inﬂuence of physiological factors on SUV of 18F-FET was similar in all
brain areas.
4. Discussion
This study shows that female gender and weakly high BMI are two
independent factors leading to signiﬁcantly increased SUVmean of 18F-
FET in the entire brain.
These relationships have not been previously known and it seems
important to discuss the inﬂuence of these parameters on the quanti-
ﬁcation of 18F-FET uptake in brain tumours. An eﬀect of gender has also
been observed for other PET tracers such as 18F-FDG showing diﬀusely
higher cerebral glucose metabolism in females than in males (Willis
Fig. 2. Anatomical localization of areas of increased SUV of 18F-FET in women in comparison with men, projected onto 3D volume rendering. SUV of 18F-FET was higher in women than
in men in diﬀuse cortical areas including frontal, parietal, temporal, and occipital lobes, as well as the cerebellum (p < 0.001 uncorrected, k > 356).
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et al., 2002; Yoshizawa et al., 2014). Earlier studies have reported that
cerebral glucose metabolism in women is 19 to 26% higher than in men
which corresponds to the proportion of higher 18F-FET uptake in the
current study (Baxter et al., 1987; Yoshii et al., 1988). A possible ex-
planation for this ﬁnding may be a higher cerebral blood ﬂow in female
patients (Yoshizawa et al., 2014) which could be linked to eﬀect of
hormones, especially estrogen, on cerebral metabolism (Reiman et al.,
1996). It was speculated that these diﬀerences in gender are applicable
to diﬀerent PET tracers (Niven et al., 2001).
The second factor in the present study that inﬂuenced SUVmean of
18F-FET weakly is BMI. We assume that diﬀerences in BMI are asso-
ciated with a diﬀerential whole-body distribution of 18F-FET. Whole-
body 18F-FET PET scans have shown that there is noticeable tracer
accumulation in the skeletal muscles and the heart with about 40% of
the total injected dose activity accumulated in muscles (Pauleit et al.,
2003). In contrast, low uptake was observed in adipose tissue. It is well
known that obese patients have a greater loss of muscle mass compared
to patients with BMI< 30 kg·m−2 (Dickerson, 2005; Port and Apovian,
2010). Moreover, there is a greater tendency to develop sarcopenia in
these patients, which is related to increased age and intramuscular fat
inﬁltration (Thornell, 2011), and overweight in elderly people induces
impaired protection mechanisms of skeletal muscle, leading to a
Fig. 3. Anatomical localization of areas of increased SUV of 18F-FET related to Body Mass Index (BMI), projected onto 3D volume rendering. BMI was positively correlated with higher
SUV of 18F-FET in diﬀuse cortical areas including frontal, parietal, temporal, and occipital lobes, as well as the cerebellum (p < 0.001 uncorrected, k > 332).
Fig. 4. Box-plots of SUVmean of 18F-FET in women and men within a fronto-parietal VOI,
used as background region. Women had higher SUVmean of 18F-FET than men
(1.47 ± 0.31 vs. 1.20 ± 0.20, p < 0.01).
Fig. 5. Correlation curve between SUVmean of 18F-FET within a fronto-parietal VOI, used
as background region, and Body Mass Index (kg/m2). SUVmean of 18F-FET was positively
correlated to BMI for women (r = 0.33 p < 0.04).
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decrease of muscle mass (Potes et al., 2017). Thus, in obese patients the
lower relative muscle mass would increase the amount of injected
tracer which is available to be delivered to the brain, leading to a higher
SUVmean of 18F-FET in the brain. This hypothesis could also partly ex-
plain the higher SUVmean of 18F-FET in the brain of women for whom
the ratio of lean to fat mass is lower than in men (Ulbrich et al., 2017).
It has to be considered, however, that both parameters were in-
dependent in multivariate analysis and the weak correlation between
SUVmean of 18F-FET and BMI could not alone explain the signiﬁcant
diﬀerence between SUVmean of 18F-FET in women and in men.
If higher SUVmean of 18F-FET in women and patients with high BMI
would have been caused by diﬀerences in cerebral blood ﬂow or in
whole-body distribution, SUV of 18F-FET uptake in the normal brain
and in brain tumours would increase to the same extent. This ﬁnding
would make the use of SUVmax and SUVmean as a direct measure to
quantify 18F-FET uptake a source of error and could inﬂuence the de-
lineation of the target volume for radiotherapy planning of brain tu-
mours as used by some authors (Rickhey et al., 2008; Vees et al., 2009;
D. C. Weber et al., 2008).
If, in the other case, the increase of SUVmean caused by gender - or
more moderately by BMI - aﬀects only 18F-FET uptake in areas of
background VOI without inﬂuencing tumour uptake, the TBR in brain
tumours would be decreased in these patient groups.
Another major ﬁnding of this study is that the inﬂuence of physio-
logical factors on SUV of 18F-FET is similar in all brain areas. Thus, 18F-
FET distribution in the brain appears to be highly stable, which suggests
that background regions in diﬀerent brain areas are equally valid for
the evaluation of TBR. Nevertheless, intra- and inter-reader variability
regarding the assessment of the background reference remains an im-
portant issue. Recently, it has been shown that background activity
assessment using a crescent-shaped volume of interest in the con-
tralateral hemisphere including white and grey matter allows mini-
mization of both intra- and inter-reader variability and might facilitate
comprehensive methodological standardization of amino acid PET,
which is of interest in the light of future technical guidelines
(Unterrainer et al., 2017). Moreover, a standardization of the reference
region is needed, while absolute values of SUV of 18F-FET could diﬀer
between areas even if they are inﬂuenced in a similar way by external
factors.
The following limitations need to be discussed. Firstly, subjects in-
cluded in this study cannot be considered as healthy subjects since all
showed brain abnormalities in MRI. For ethical reasons, however, it
would be diﬃcult to investigate such a large number of healthy subjects
by 18F-FET PET. In addition, each scan was carefully checked before
inclusion to ascertain its negative state with regard to 18F-FET uptake.
Secondly, scans were performed on two diﬀerent PET systems.
However, the quantitative analysis did not show an eﬀect of type of PET
scanner on SUV of 18F-FET uptake and this parameter was included as a
covariate in our statistical model. Finally, a whole-brain quantitative
analysis has been performed although the areas with suspicious brain
lesions as identiﬁed on MRI have not been excluded from the VOI
analyses. The brain lesions areas were nevertheless indistinguishable
from that of the normal brain, as reported in the Materials and methods
section and were diﬀerently located for each individual subjects,
making it almost unlikely to inﬂuence overall results of group analysis.
5. Conclusion
In summary, SUVmean of 18F-FET in the normal brain is inﬂuenced
by gender and weakly by BMI. We suggest that these ﬁndings are partly
caused by diﬀerent whole-body distribution of 18F-FET depending on
the muscle mass but other gender speciﬁc factors dominate. The in-
ﬂuence of these factors on SUV of 18F-FET is similar in all brain areas.
However, although 18F-FET distribution in the normal brain appears to
be highly stable, a standardization of the reference region is necessary
for comparison of data between diﬀerent centres.
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